Business
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies Begins GMP Manufacturing Of Cannabinoid-Based Gum With Dronabinol For Use In Upcoming Clinical Studies\nPR Newswire\nSAN DIEGO, Sept. 12, 2019\n\n\n\nSAN DIEGO, Sept. 12, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (\"the Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its major investment company AXIM® Biotechnologies, Inc. (\"AXIM® Biotech\" or \"AXIM\") (OTCQB: AXIM) has begun manufacturing its cannabinoid-based chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC). \nThe chewing gum, manufactured through AXIM's contract manufacturer, Eurofins Amatsigroup in Belgium, is intended for use in AXIM's upcoming clinical studies on cannabis as a treatment for chemotherapy-related symptoms. \nAccording to the Center for Disease Control and Prevention (CDC), about 650,000 cancer patients in the U.S. receive chemotherapy each year with an average cost of $100,000 per patient per year. Symptoms that many chemotherapy patients experience include a weakened immune system, pain, nausea, vomiting, and diarrhea. \n\"Medical Marijuana, Inc. has always supported the efforts of AXIM to conduct research that allows them to provide those in need with innovative delivery mechanisms,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"We look forward to the findings of AXIM's upcoming dronabinol chewing gum studies and understanding how it may help those undergoing chemotherapy.\"\nIn the coming months, AXIM intends to conduct a bioequivalence study between its chewing gum with dronabinol and FDA-approved capsules containing dronabinol – and later provide evi...